Eloralintide

Synonyms: LY3437943, GIP/GLP-1/glucagon receptor triagonist, Retatrutide analog, Triple agonist peptide

Eloralintide is a synthetic peptide engineered as a triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Its design incorporates structural motifs from native incretin hormones, with modifications to enhance stability and receptor affinity. The peptide backbone features a C-terminal amide and fatty acid side chain for prolonged half-life, making it a promising candidate for metabolic disorders.

Developed by LyvBio, Eloralintide is produced via solid-phase peptide synthesis and purified using preparative HPLC. It is supplied as a lyophilized powder with high purity, suitable for preclinical and clinical research. The compound is intended for investigation in obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH) models.

With its unique triple agonist profile, Eloralintide offers a novel approach to modulating multiple metabolic pathways simultaneously. Researchers are exploring its potential to improve glycemic control, reduce body weight, and enhance lipid metabolism. This product is for research use only and not for human consumption.

Chemical Structure & Properties

Eloralintide is a 39-amino acid peptide with a molecular weight of approximately 4970 Da. It contains non-natural amino acids and a palmitic acid moiety conjugated via a linker to lysine residues, which facilitates binding to serum albumin and extends its circulation time. The peptide is highly soluble in aqueous solutions at neutral pH and exhibits stability when stored desiccated at -20°C.

Mechanism of Action

• GIP receptor agonism: Enhances insulin secretion in a glucose-dependent manner and may improve adipose tissue function.
• GLP-1 receptor agonism: Suppresses glucagon release, slows gastric emptying, and promotes satiety, leading to reduced food intake.
• Glucagon receptor agonism: Increases energy expenditure and lipolysis, contributing to weight loss and improved lipid profiles.
• Synergistic metabolic effects: The combined activation of three receptors amplifies beneficial effects on glucose homeostasis and body weight regulation.

Quality Specifications

Supply & Documentation

• Capacity: 100 g per month
• Lead time: 3-5 business days (stock items)
• Documentation: COA, MSDS, TDS, HPLC chromatogram
• Packaging: 5 mg, 10 mg, 50 mg, 100 mg in glass vials with desiccant

Request For Quote

• LyvBio Co., Ltd. — Email: info@lyvbio.com